Sonoma Biotherapeutics Receives $45M Milestone Payment from Regeneron for Treg Therapy Collaboration
Slice of Healthcare Team
Sep 05, 2024
Key Highlights
- Sonoma Biotherapeutics receives $45 million milestone payment from Regeneron.
- Collaboration focuses on engineered Treg therapies for autoimmune diseases.
- Sonoma Bio retains co-promotion rights in the U.S. for future products.
- Regeneron has the option to lead late-stage global commercialization.
Source: Business Wire
Notable Quote
“ This payment marks a significant milestone in our evolution as a company and our collaboration with Regeneron, which has been going extremely well. ”
Jeff Bluestone, Ph.D., Chief Executive Officer at Sonoma Biotherapeutics
